The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®)
نویسندگان
چکیده
منابع مشابه
AmBisome today: expanding the perspectives on liposomal amphotericin B.
considered by many to be the gold standard for the treatment for numerous invasive fungal infections for over 45 years, toxicities associated with its use often necessitate treatment modifications or discontinua-tion. Lipid-based formulations, including liposomal amphotericin B were developed to decrease many of these toxicities. These agents have proven their value in a variety of clinical set...
متن کاملImmediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
Liposomal amphotericin-B (AmBisome) is now becoming first choice for the treatment of visceral leishmaniasis (kala-azar) patients due to high efficacy and less toxicity. The reported incidence of hypersensitivity reactions to liposomal amphotericin-B (AmBisome), especially during therapy, is very rare. We report two patients with kala-azar: one developed breathing difficulties and hypotension f...
متن کاملLiposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
Liposomal amphotericin B (AmBisome(®); LAmB) is a unique lipid formulation of amphotericin B. LAmB is a standard of care for a wide range of medically important opportunistic fungal pathogens. LAmB has a significantly improved toxicity profile compared with conventional amphotericin B deoxycholate (DAmB). Despite nearly 20 years of clinical use, the pharmacokinetics and pharmacodynamics of this...
متن کاملRole of liposomal amphotericin B (AmBisome) in the prophylaxis of mycoses after liver transplantation.
The incidence of invasive fungal infection (IFI) after liver transplantation (LTx) ranges from 5 to 42% [1]. Candida albicans and Aspergillus fumigatus are the most common pathogens in liver graft recipients, who are more susceptible to IFIs than any other type of solid organ transplant recipient. Onset of fungal infection is mainly within the first two months after LTx which is associated with...
متن کاملPlasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Unilamellar liposomal amphotericin B (AmBisome) (liposomal AMB) reduces the toxicity of this antifungal drug. The unique composition of liposomal AMB stabilizes the liposomes, producing higher sustained drug levels in plasma and reducing renal and hepatic excretion. When liposomes release their drug payload, unbound, protein-bound, and liposomal drug pools may exist simultaneously in the body. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Liposome Research
سال: 2017
ISSN: 0898-2104,1532-2394
DOI: 10.1080/08982104.2017.1380664